Pharmaceuticals

Foyou Pharma

Foyou Pharma released FY2026 Q1 earnings on April 24 After-Market BJT, actual revenue CNY 811.17 M, actual EPS CNY 0.2

Foyou Pharma to Release FY2026 Q1 Earnings on April 25 After-Market BJT

Foyou Pharma released FY2025 Q4 earnings on April 13 After-Market (BJT), actual revenue CNY 983.84 M, actual EPS CNY 0.2167

Foyou Pharma released FY2025 Annual Earnings on April 13 After-Market (BJT), actual revenue CNY 3.504 B, actual EPS CNY 1

Foyou Pharma to Release FY2025 Earnings on April 14 After-Market (BJT)

Foyou Pharma released FY2025 9 Months Earnings on October 29 After-Market (BJT), Actual Revenue: CNY 2.521 B, Actual EPS: CNY 0.7809

Foyou Pharma released FY2025 Q3 earnings on October 29 After-Market (BJT), actual revenue CNY 886.63 M, actual EPS CNY 0.2207

Foyou Pharma to Release FY2025 Q3 Earnings on October 30 After-Market (BJT)

Foyou Pharma released FY2025 Q2 earnings on August 18 During-Market (BJT), actual revenue CNY 803.5 M, actual EPS CNY 0.2902

Foyou Pharma released FY2025 Semi-Annual Earnings on August 18 During-Market BJT, with actual revenue of CNY 1.634 B and EPS of CNY 0.56

Foyou Pharma to Release FY2025 Semi-Annual Earnings on August 19, 2025 (BJT)

Fu Yuan Pharmaceutical Stock Abnormal Fluctuation

Fuyuan Pharma's FY101 Injection Receives Clinical Trial Approval

Fuyuan Pharmaceutical Approved to Produce Lansoprazole Enteric-Coated Capsules by NMPA

Fullon Pharma Introduces Progress in Innovative Drug R&D

Taiping Researcher Zhou Yu Publishes Report on Fuyuan Pharmaceutical

Pacific Researcher Zhou Yu Publishes Buy Rating Report on Fuyuan Pharmaceutical

Fuyuan Pharmaceutical Obtains Certificate for Benidipine Hydrochloride Tablets

Fuyuan Pharmaceutical Obtained the Drug Registration Certificate for Amorolfine Hydrochloride Lotion

Fuyuan Pharmaceutical Obtains Drug Registration Certificate for Lidocaine Prilocaine Cream

601089

Foyou Pharma announced that six of its products are expected to be selected in the 11th batch of national centralized drug procurement, including Fumaric Acid Lurasidone Tablets, Pravastatin Sodium Tablets, Cilostazol Tablets, Alendronate Sodium Tablets, Agomelatine Tablets, and Dopamine Hydrazine Tablets. If these products are selected and sales contracts are signed, it will help increase market share and have a positive impact on the company's future operating performance. At the same time, the products that the company did not win bids for, such as Dapagliflozin Tablets, did not generate sales in 2024, and the sales amount from January to September 2025 was CNY 2.9413 million, accounting for 0.1167% of the company's operating income during the same period, which will not have a significant impact on the company's production and operations

Zhitong

Foyou Pharma: 6 products are expected to be selected for the 11th batch of national centralized drug procurement

According to the Zhitong Finance APP, Foyou Pharma announced that it has recently received the "Approval Notice for the Market Application of Chemical Raw Materials" for Clobetasol from the National Medical Products Administration. Clobetasol is suitable for topical treatment of mild to moderate atopic dermatitis in patients aged 2 years and older. The company's acquisition of the "Approval Notice for the Market Application of Chemical Raw Materials" for Clobetasol will further enrich the company's product line and promote its continuous, stable, and healthy development

Foyou Pharma has obtained the approval notice for the listing application of Clobazam raw materials

According to the Zhitong Finance APP, Foyou Pharma announced that its wholly-owned subsidiary Zhejiang Aisheng Pharmaceutical Co., Ltd. (referred to as "Zhejiang Aisheng") has received the Drug Registration Certificate for Dydrogesterone Tablets (Specification: 10mg) issued by the National Medical Products Administration, approving the production of this drug. Dydrogesterone is an orally absorbable synthetic progestogen

Foyou Pharma: Dydrogesterone Tablets Obtained Drug Registration Certificate

Foyou Pharma recently obtained the drug registration certificate for Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) issued by the National Medical Products Administration, approving the production of this drug. This drug is a compound preparation that contains Candesartan Cilexetil and Hydrochlorothiazide, suitable for adults with primary hypertension who cannot effectively control their blood pressure

Foyou Pharma: Candesartan Cilexetil and Hydrochlorothiazide Tablets (II) has obtained the drug registration certificate

688166

600211

Innovative drug concept stocks continue to decline, BrightGene fell over 8%, TIBET PHARMA fell over 7%, Foyou Pharma, Zhendong Pharmaceutical, and Maiwei Biotech all dropped

BrightGene

TIBET PHARMA

Innovative drug concept stocks continue to decline, BrightGene falls over 8%

Foyou Pharma recently obtained the drug registration certificate for Pioglitazone and Metformin Tablets (15mg/850mg) issued by the National Medical Products Administration, approving the production of this drug. This drug is suitable for patients with type 2 diabetes, especially those who do not respond well to existing treatments. The original research company is Takeda Pharmaceutical Company Limited, and this drug has not yet been launched in China

Foyou Pharma: Pioglitazone and Metformin Tablets (15mg/850mg) have obtained the drug registration certificate

Foyou Pharma recently obtained the Drug Registration Certificate for Arolol Hydrochloride Tablets (10mg) issued by the National Medical Products Administration, approving the production of this drug. This drug is used to treat primary hypertension, angina pectoris, tachycardic arrhythmias, and essential tremor. This registration will enrich the company's product line and enhance its market competitiveness

Foyou Pharma: Hydrochloride Arolol Tablets have obtained the drug registration certificate

In the morning session, the innovative drug concept experienced fluctuations and adjustments, with Foyou Pharma hitting the limit down, Frontier Biotech falling over 10%, and multiple stocks such as Baihua Medicine, Jimin Health, Shutai Shen, Baili Tianheng, and Chengdu Xian Dao dropping over 5%

Innovative drug concept adjusts at the beginning of the session, Foyou Pharma hits the limit down

Foyou Pharma recently obtained the drug registration certificate for Amlodipine Benazepril capsules issued by the National Medical Products Administration, approving the production of this drug. This drug is used to treat hypertension and is suitable for patients whose blood pressure cannot be satisfactorily controlled by taking Amlodipine or Benazepril alone, or as an alternative treatment

Foyou Pharma: Amlodipine Benazepril Capsules have obtained the drug registration certificate

300255

300363

688658

688221

Innovative drug concept stocks rose at the beginning of trading, with YKYY up over 10%, Froniter Biotechnologies up over 9%, and CSBIO, Porton, and Foyou Pharma leading in gains

CSBIO

Porton

YKYY

Froniter Biotechnologies

Innovative drug concept stocks rose at the beginning of the trading session, YKYY increased by over 10%

Foyou Pharma(601089.SH)